Newsletter | August 25, 2026

08.25.26 -- What The China Biotech Debate Reveals About U.S. Drug Discovery

SPONSOR

Discovery & Development US 2026 puts your brand in front of thousands of biopharma decision-makers. 52% from pharma and biotech, 60% actively budgeted for new solutions. Through immersive sponsorship formats, guaranteed 1:1 meetings with pre-qualified buyers, audience engagement data, and tailored media coverage, it's a platform built to accelerate your pipeline conversations and visibility in one place.

FEATURED EDITORIAL

What The China Biotech Debate Reveals About U.S. Drug Discovery

Peter Kolchinsky and Jason Kelly sparred over China’s biotech rise and what it means for U.S. drug discovery, investment, and strategic control.

Synaptic Regeneration And The Future Of Alzheimer's R&D

For too long, treating Alzheimer’s disease has been a case of “managed decline.” We need to move beyond slowing disease progression toward achieving tangible functional recovery.

Why Tolerability Will Drive The Next Wave Of Obesity Treatments

For the next generation of obesity medicines, enhancing how patients experience therapy will inform discovery and development efforts and may ultimately determine long-term success.

INDUSTRY INSIGHTS

In Vitro Dissolution Methodologies For Amorphous Solid Dispersions

With the availability of so many types of in vitro dissolution tests, how do you determine which one will be most effective in predicting in vivo performance of your BCS II or IV drug product?

Rapid And Sensitive Detection Of Replication-Competent Lentivirus (RCL)

See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.

How Isogenic Organ-Chips Are Transforming The Future Of Research

Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.

mRNA LNPs Drive Safe, Effective Repeat Dosing In Disease Models

Well-designed lipid nanoparticles enable safe, efficient delivery. OVA-based models show how formulation choices shape efficacy, safety, and anti-tumor outcomes in melanoma research.

Detect Rare, Low-Expressing BCMA CAR-T Cells In One Step

Discover how precise flow cytometric identification of CAR+ cells across diverse models and workflows enables high specificity, flexibility, and sensitivity—even in rare or low-expression populations.

Solid Form Screening, Rapid Formulation Selection To Meet Tight Timelines

A comprehensive approach to evaluating drug molecules for the selection of a lead solid form and formulation can significantly accelerate development timelines and limit risks in later development.

SPONSOR

Join us September 9, 2026, at 10 a.m. ET for Inside the Organoid Services Ecosystem for Drug Discovery. Explore how organoids and other NAMs are advancing drug discovery and translational research, including insights from the NIH Standardized Organoid Modeling Initiative. Discover opportunities, challenges, and practical considerations for scaling organoid technologies and integrating standardized platforms into biopharmaceutical development workflows. Register online today.

SOLUTIONS

Phage And Yeast Display

Designed For Difficult Biology